Search results
Piper Sandler keeps Zscaler shares target unchanged, underscores strategic growth By Investing.com
Investing.com· 10 hours agoOn Thursday, Piper Sandler confirmed its Overweight rating on Zscaler (NASDAQ:ZS) with a steady...
Investors in Piper Sandler Companies (NYSE:PIPR) have seen solid returns of 224% over the past five...
Simply Wall St. via Yahoo Finance· 1 day agoThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all...
JMP Securities Reiterates Market Perform Rating for Piper Sandler Companies (NYSE:PIPR)
ETF DAILY NEWS· 21 hours agoPiper Sandler Companies (NYSE:PIPR – Get Free Report)‘s stock had its “market perform” rating...
Why is Katie Piper missing her Breakfast Show and when is she back?
Yahoo Celebrity UK· 2 days agoKatie Piper has had to miss her Breakfast Show. (Getty Images) Jeff Spicer via Getty Images Katie ...
Ex-Goldman Sachs employee says she felt ‘violated’ during faked YouTube exec call
Courthouse News Service· 2 hours ago“Hillel, is that you?” Berardo recalled the person on the other end of the call saying. Since Piper...
JPMorgan stock maintains Overweight rating with upbeat revenue outlook By Investing.com
Investing.com· 10 hours agoOn Thursday, Piper Sandler sustained its Overweight rating and $220.00 price target for JPMorgan...
2024 WWE Clash at the Castle predictions, card, matches, PPV preview, start time, date, location
CBS Sports· 2 hours agoWWE hosts a pay-per-view event in Scotland for the first time this Saturday when Clash at the Castle...
Piper Sandler Companies (NYSE:PIPR) Reaches New 12-Month High at $206.69
ETF DAILY NEWS· 4 days agoPiper Sandler Companies (NYSE:PIPR – Get Free Report)’s share price hit a new 52-week high during...
Piper's Angels on a mission to help those with cystic fibrosis
WPBF West Palm Beach· 1 day agoNEXT WEEK IS THE LANDING PARTY FOR THE CROSSING FOR CYSTIC FIBROSIS. JOINING ME TO TALK ABOUT THE...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 8 hours agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...